BMC, acting as an external expert, valued R&D programmes of the OncoArendi Therapeutics in the process of valuation of the company for tranactional purposes. OncoArendi Therapeutics closed on 15th January 2015 a Series A financing round with Michał Sołowow as a leading investor acting via the IPOPEMA 112 FIZAN fund. OncoArendi is a dynamically growing biotechnological… Read more »
Partnership with PANWIM Technologie
BMC and PANWIM Technologie Sp. zo.o.- a special purpose company founded by the Institute of Fundamental Technological Research, Polish Academy of Sciences and the Military Institute of Medicine- are pleased to announce formation of a partnership in the area of technology transfer and commercialization of research and development projects. PANWIM Technolgie was created as a… Read more »